UM Ventures Congratulates Tokai Pharma on Recent Fundraising Success
Wednesday, May 15, 2013
Tokai’s lead drug candidate, galeterone (TOK-001), is currently in Phase 2 clinical trials as a new therapy against prostate cancer. Galeterone was discovered by a UM Baltimore research team led by Prof. Angela Brodie and Prof. Vincent Njar.
Read more at:
http://tokaipharma.com/pdfs/Tokai-Series-E-Financing-PR-FINAL-51513.pdf
http://www.umgcc.org/news/angela-h-brodie.htm
http://medschool.umaryland.edu/cbt/